Apellis Pharmaceuticals, Inc. (APLS) Misses Q3 EPS by 18c

Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) reported Q3 EPS of ($1.17), $0.18 worse than the analyst estimate of ($0.99). Revenue for the quarter came in at $110.4 million versus the consensus estimate of $99.38 million.

For earnings history and earnings-related data on Apellis Pharmaceuticals, Inc. (APLS) click here.

You May Also Be Interested In

• Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
• Morgan Stanley Resumes Bath & Body Works Inc. (BBWI) at Equalweight
• ArcelorMittal (MT:NA) (MT) PT Raised to EUR65 at Jefferies